Cardiogenic shock (CS) is associated with a high rate of in-hospital mortality and a poor prognosis. Inotropic agents, used in clinical practice, remain the cornerstone of the management of CS. Dobutamine is the most usually preferred in this indication. Despite its benefit effects, this drug also exerts adverse effects as sinus tachycardia, possibly deleterious in this context. In the recent ESC guidelines (Ponikowski et al. 2016) , inotropic agents are clearly not recommended for the management of a patient with acute HF unless the patient is symptomatically hypotensive or hypoperfused because of safety concern (class III, A). Shortterm, intravenous infusion of inotropic agents may be considered in patients with hypotension (SBP < 90 mmHg) and/or signs of hypoperfusion (despite adequate volemia), in order to maintain and improve the cardiac outflow, peripheral perfusion and maintain end-organ function (class IIb, level C). Dobutamine has even been suggested to increase mortality (O'Connor et al. 1999 , Wang et al. 2015 .
The level of recommendation and the years of publications of main trials in the field underline that we lack data, regarding both basic models and clinical trials.
We lack strong clinical data in the field. Only few trials are currently studying CS (Table 1) . As indicated in the Table 1 , there are some epidemiological or prognostic evaluations, some trials on mechanical assistances and devices, but surprisingly few studies with drugs (and none evaluating ivabradine in this context to our knowledge). A few years ago, the interest of intra-aortic balloon support for patients with acute myocardial infarction leading to CS has been definitely challenged (Thiele et al. 2012 (Thiele et al. , 2013 , reinforcing the lack of trials and recommendations with strong level of evidence.
Even epidemiological data are rather scarce and local uses are heterogeneous. Recently, a multi-centre study (Harjola et al. 2015) included in nine centres representing eight countries. A total of 219 patients were included over 2 years, underlining the high difficulties to conduct a trial in the field. Consistently, FRENCHSHOCK, a French nationwide registry, is currently ongoing (NCT02703038). Its aim is to reflect the current practice in the field, including the likely heterogeneous clinical strategies, in a nationwide registry, in the as short as possible framework (>500 patients in less than 6 months).
Importantly, this registry aims to present real-life clinical features and management of more than 500 patients in various centres. The current management of CS is indeed crucial including the real use of inotropic drugs and their prognostic impact.
We lack basic data in the field. In the study published in this journal, Bakkehaug et al. (2016) reported a basic model of CS (Bakkehaug et al. 2016) .
The aim of the authors was to evaluate the effect of a combined therapy by dobutamine and ivabradine in a model of post-ischaemic low cardiac output.
Indeed, both inotropic impact and induced tachycardia by dobutamine participate to increase the cardiac output in CS. On the other hand, the induced sinus tachycardia could exert in turn deleterious effects (we could also cite other side effects such as arrhythmias). Indeed, increased tachycardia may increase left ventricular work inducing myocardial ischaemia and shortening diastole period and then efficient ventricular filling.
Ivabradine is a specific blocker of the If funny current supported by the hyperpolarization-activated cyclic nucleotide-gated channels. This ionic current is involved in activity of the sinoatrial node. The interest of ivabradine is the reduction of heart rate without depressing myocardial inotropism or decreasing cardiac output . This reduction remains mild (about 9 bpm in the clinical trials in patients with HF), which appears compatible with haemodynamics adaptation and not compromising this adaptive tentative, hence its theoretical interest in this setting , Lattuca & Roubille 2015 .
Ivabradine is currently indicated in chronic heart failure (class IIa, level B), in patients in sinus rhythm with a left ventricular ejection fraction <35% and heart rate <70% despite treatment with an evidence-based dose of beta-blockers, angiotensin-converting enzyme inhibitor and a mineralo-corticoid receptor antagonist (Ponikowski et al. 2016) . Importantly, it is currently not recommended in patients with acute HF as no randomized large trials addressed this issue. Only few data are available concerning its indication in CS. Bakkehaug et al. (2016) proposed a double approach to assess the effects of this pure negative chronotropic drug without inotropic depression in the context of CS: 1 They firstly studied the interest of ivabradine in a large-animal model. An ischaemia-reperfusion protocol was performed in 12 pigs after intermittent ligation of the left coronary arteries under general anaesthesia. Haemodynamic and energetic measurements by intracardiac catheterism and sonomicrometry crystals were performed to assess several data, mainly heart rate, cardiac output, stroke volume, stroke work, myocardial oxygen consumption, end left ventricular systolic and end-diastolic dimension and diastolic filling time.
Effects of a treatment regimen compounded only with dobutamine on these parameters were compared to the combination of dobutamine-ivabradine.
Introduction of dobutamine in post-ischaemic heart (5 lg kg À1 min À1 ) increased cardiac output by increasing significantly heart rate from 102 AE 21 to 131 AE 16 bpm (P < 0.05).
The analysis demonstrated that an adjunction of ivabradine in the pigs treated with dobutamine permitted to decrease heart rate to the baseline (100 AE 9 bpm) without any effect on cardiac output or blood pressure.
The second main result was the positive impact of ivabradine on stroke volume, from 30 AE 5 to 36 AE 5 mL (P < 0.05) mainly by increasing the diastolic filling and the end-diastolic dimensions. No effect was found concerning the myocardial energetic consumption. 2 They confirmed the data obtained in the first model in a second model of heart of ex vivo mice using a Langendorff model. Hearts of 16 mice were removed and a 40 min of ischaemia was performed followed by 5 min of reperfusion. Isoproterenol was used, increasing myocardial oxygen consumption and cardiac output, similarly due to an elevation of heart rate. Ivabradine was then added and permitted to return the heart rate to baseline reducing myocardial oxygen consumption. The stroke volume tended to increase (P = ns). This study is innovative in the field of CS and shows by two different protocols and in two different animal models (rodent and pig) a benefit of ivabradine as regards haemodynamic parameters.
The main limit is that measurement was taken in stable haemodynamic conditions which is difficult to extend to clinical practice with most of time unstable patients.
Ivabradine is well known to exert positive effects in the context of stable heart failure by decreasing heart rate and then myocardial oxygen consumption and is indicated in this context (Ponikowski et al. 2016) . AMI, acute myocardial infarction; CS, cardiogenic shock; ECLS, extracorporeal life support; ECMO, extracorporeal membrane oxygenation; IV, Intravenous; LVEF, left ventricular ejection fraction; OMT, optimal medical therapy; PCI, percutaneous coronary intervention; STEMI, ST-segment elevation myocardial infarction.
84 studies are registered on 'clinicaltrials.gov' on May 2016 (when discard the studies terminated (n = 37) , withdrawn (n = 2) or when status remains unknown (n = 10). Only trials including patients exclusively with CC requiring medical management are presented (for instance patients benefiting from a PCI at high risk or in a surgical context are not presented).
In the context of CS treated with dobutamine, ivabradine could exert a beneficial effect regarding to the decrease in heart rate, reducing also arrhythmias, myocardial ischaemia and potentially myocardial energetic consumption (Fig. 1) .
Clinical trials are difficult to initiate in patients with CS due mainly to their unstable status and high rate of mortality. In a recent paper, the authors reported promising data by adding ivabradine 5 mg twice daily in patients treated with dobutamine infusion for a refractory CS (n = 9) (Gallet et al. 2014) . They showed that ivabradine allowed to improve diastolic filling time without decreasing cardiac output. At 24 h, an increase in systolic blood pressure, daily urine output, oxygen balance and NT-proBNP level was noticed. This pilot study highlighted the safety and a potential benefit of ivabradine in the context of CS under inotropic support.
In conclusion, results presented in the paper of Bakkehaug et al. (2016) are promising and have to be confirmed by a clinical study to assess the effect of this strategy in the aim to counteract deleterious effects of dobutamine in patients with CS all the more as we lack data and because of poor outcomes in this setting. Acute compensatory mechanisms Figure 1 Schematic presentation of the theoretical interest of ivabradine in cardiogenic shock. Initial contractility and inotropism failure lead to cardiogenic shock and induce compensatory mechanisms such as increased heart rate to maintain effective cardiac output. As a side effect, this compensatory phenomenon results in an increase in oxygen consumption and decrease in systolic ejection volume, leading to a vicious circle. On the one hand, the introduction of dobutamine could restore inotropism [1] . On the other hand, it could participate in tachycardia leading to diastolic impairment [2, 3] . The combined use of a pure heart rate lowering agent such as ivabradine would limit this increase in heart rate and then break the vicious circle [4, 5] . Adapted from Lattuca and Roubille (2015) .
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